Search Results
10
Everything
GRI Bio Announces Closing of $5.0 Million Public Offering
April 02, 2025 16:05 ET
|
GRI Bio, Inc.
LA JOLLA, CA, April 02, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell...
GRI Bio Announces Pricing of $5.0 Million Public Offering
April 01, 2025 11:15 ET
|
GRI Bio, Inc.
LA JOLLA, CA, April 01, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell...
GRI Bio Reports Encouraging Interim 2-Week Safety Results from Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)
April 01, 2025 09:00 ET
|
GRI Bio, Inc.
The Independent Data Monitoring Committee (IDMC) has recommended to continue study as planned as there are no safety concerns seen in the data reviewed Interim results demonstrate GRI-0621 to be safe...
GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan
March 31, 2025 08:00 ET
|
GRI Bio, Inc.
Company committed to building a robust global patent estate across its innovative pipeline of NKT cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases LA JOLLA, CA,...
GRI Bio Participates in a Virtual Investor CEO Connect Segment
March 18, 2025 09:05 ET
|
GRI Bio, Inc.
Access the CEO Connect segment here LA JOLLA, CA, March 18, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative...
GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)
March 17, 2025 08:05 ET
|
GRI Bio, Inc.
Interim data and topline data readouts from Phase 2a biomarker study expected in Q2 2025 and Q3 2025, respectively Cash runway expected to fund operations into Q2 2025, including interim data...
GRI Bio Regains Compliance with Nasdaq’s Minimum Bid Price Rule
March 11, 2025 08:35 ET
|
GRI Bio, Inc.
LA JOLLA, CA, March 11, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell...
GRI Bio Announces Reverse Stock Split
February 19, 2025 16:05 ET
|
GRI Bio, Inc.
GRI’s common stock is expected to begin trading on a post-split adjusted basis on February 24, 2025 LA JOLLA, CA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the...
GRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
February 19, 2025 09:00 ET
|
GRI Bio, Inc.
On-demand video webcast now available here LA JOLLA, CA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative...
GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds
December 23, 2024 09:00 ET
|
GRI Bio, Inc.
– Company committed to building a robust global patent estate across its innovative pipeline of NKT cell modulators LA JOLLA, CA, Dec. 23, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI...